Menú Cerrar

Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan

KotaMorishitaabShinichiYamadaaAkikoKawakitabMasaoHashidumeaAkiraTachibanacNoritamiTakeuchidYumikoOhbayashieTakahiroKannofDaigoYoshigagTakashiNaraihNoboruSasakiiHisayukiShinoharajNarikazuUzawakMinoruMiyakeeKazuhiroTominagalIsamuKodanihMasahiroUmedabHiroshiKuritaa

https://doi.org/10.1016/j.jos.2020.01.012Get rights and content

Abstract

Background

Therapeutic strategies for patients with medication-related osteonecrosis of the jaw (MRONJ) remain controversial. The aim of the present study was to clarify the effectiveness and safety of teriparatide therapy in Japanese MRONJ patients based on a large number of case series with a multicenter retrospective analysis.

Patients and methods

Between January 2012 and December 2016, 29 patients who were diagnosed with MRONJ at 10 hospitals were treated with teriparatide. The medical records of these patients were retrospectively reviewed to assess the efficacy and safety of teriparatide therapy for MRONJ patients.

Results

Adverse events occurred in 17.2% of patients (5/29). One patient developed severe arthralgia and discontinued teriparatide therapy after 12 days, while others continued the treatment. Among 29 patients, the median period of administration of teriparatide was 14.0 months (range, 0.3–26 months), and treatment outcomes were evaluated as effective in 75.9% of patients with complete resolution in 65.5%. Among patients treated with oral bisphosphonates (BPs), 83.3% were effectively treated with teriparatide and 40% with intravenous BPs. The oral administration of BPs was associated with successful treatment outcomes with teriparatide (p = 0.062).

Conclusions

Teriparatide therapy has potential as an effective treatment option for MRONJ.